Olink Insight Unveils Open-access Map of the Human Proteome, Aiding Biomarker Discovery and Understanding of Disease
UPPSALA, Sweden, April 2, 2024 — Olink Holding AB (publ) (Nasdaq: OLK) today announced the availability of an open access data library consisting of over 300,000 protein-disease risk associations, giving researchers a powerful new tool for revealing the biological mechanisms underlying 106 human diseases.
In April 2023, the UK Biobank Pharma Proteomics Project (UKB-PPP) released data produced from over 50,000 samples analyzed using the Olink® Explore platform. The UKB-PPP is the largest population-scale proteomics study to date, yielding an unprecedented view into the biology of diseased and healthy individuals over a 10-year period. By combining protein measurements with longitudinal healthcare data for each of the individuals, Olink derived the estimated effects of ~3,000 proteins on the future risk of disease.
The derived data library is available within Olink Insight. Olink Insight is a free, web-based platform that puts the results of advanced computational data analysis into the hands of non-data scientists. In just a few clicks scientists can quickly go from raw experimental results to the identification of significant hits, overlaid with information on tissue specificity, disease associations, and variability in normal cohorts.
A detailed presentation of how scientists can leverage this data for uncovering disease-specific biomarkers or elucidating the involvement of biomarkers across multiple diseases will be presented in a technical webinar on April 24, 2024.
The disease risk data contained in the library will enable researchers to better understand critical drivers across a broad spectrum of diseases from inflammatory pathways to prostate cancer. The data are a powerful tool for exploring the role of key proteins such as FCRL2 in critical processes like B cell development and chronic lymphocytic leukemia (CLL).
“UK Biobank is the world’s leading biomedical data resource, powering research that will improve the health of the public across the globe,” said Dr. Lucy Burkitt-Gray, Lead Data Analyst, UK Biobank. “The Olink findings correlating protein levels to disease risk are one of many prime examples of how the large-scale UK Biobank cohort data on half a million volunteers is contributing to our understanding of how protein expression affects health.”
“We are tremendously excited to add this rich dataset, revealing important protein-disease associations, to the Olink Insight platform which represents a significant realization of the potential of the UK Biobank data while also further reducing the barrier to access,” says Ida Grundberg, Chief Scientific Officer at Olink. “These data provide essential insights into the biology of disease, allowing researchers to better understand their findings and accelerate the understanding of disease progressions and treatment effects.”
The open-access disease risk data library is another example of Olink’s active partnership with the scientific community to advance our understanding of how individual differences impact disease progression and treatment. Together with industry leading proteomics products and services, Olink is committed to delivering complete end to end solutions that help researchers realize the promise of precision medicine.
For more information, please contact:
Investor contact
Oskar Hjelm
Chief Financial Officer
Mobile: +46 733502932
oskar.hjelm@olink.com
Media contact
Michael B. Gonzales, PhD
Vice President, Global Marketing
Mobile: +1 415 308 6467
michael.gonzales@olink.com
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.